# Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

> **NCT06028633** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Advanced Non-squamous Non-small-cell Lung Cancer
- Recurrent Non-Squamous Non-Small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer

## Interventions

- **DRUG:** pembrolizumab
- **DRUG:** lenvatinib
- **DRUG:** albumin-bound paclitaxel

## Key facts

- **NCT ID:** NCT06028633
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10
- **Primary completion:** 2024-10
- **Final completion:** 2026-10
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2023-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06028633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06028633, "Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06028633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*